Literature DB >> 29618021

Persistence of Diabetes and Hypertension After Multimodal Treatment of Acromegaly.

Baldomero González1, Guadalupe Vargas1, Ana Laura Espinosa de Los Monteros1, Victoria Mendoza1, Moisés Mercado1.   

Abstract

Context: Diabetes and hypertension are frequent comorbidities of acromegaly. Objective: To analyze the course of diabetes and hypertension at diagnosis and after multimodal therapy in a large cohort of patients with acromegaly. Design and Setting: Retrospective study at a tertiary care center. Patients and
Methods: A total of 522 patients with acromegaly treated according to a preestablished protocol. Main Outcome Measures: Prevalence of diabetes and hypertension and its relationship with biochemical indices of acromegalic control.
Results: The cohort was stratified according to disease activity upon last visit to clinic: (1) surgical remission (n = 122), (2) pharmacologically controlled (n = 92), (3) active disease (n = 148), (4) insulinlike growth factor (IGF)-1 discordance (n = 64), and (5) growth hormone (GH) discordance (n = 96). The prevalence of diabetes and hypertension at diagnosis was 30% and 37%, respectively, and did not change upon the last visit (30.6% and 38%). Both comorbidities were more prevalent at diagnosis and on the last visit than in the general population. Diabetes was less prevalent on the last visit in patients who achieved surgical remission than in those who persisted with active disease (25% vs 40%, P = 0.01). Upon multivariate analysis, diabetes was associated with an IGF-1 at diagnosis >2× upper limit of normal, with the persistence of active acromegaly, the presence of hypertension upon the last visit, with the presence of a macroadenoma, and with female sex.
Conclusion: Our findings underscore the importance of an integral approach when managing these patients, focusing not only on the control of GH and IGF-1 levels but also on the timely diagnosis and the specific treatment of each comorbidity.

Entities:  

Mesh:

Year:  2018        PMID: 29618021     DOI: 10.1210/jc.2018-00325

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Body Composition in Acromegaly According to Disease Activity - Performance of Dual X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis.

Authors:  Aline Alves Lopes; Luciano Albuquerque; Mayara Fontes; Daniella Rego; Francisco Bandeira
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-18       Impact factor: 6.055

Review 2.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

Review 3.  The Interaction of Insulin and Pituitary Hormone Syndromes.

Authors:  Marie Helene Schernthaner-Reiter; Peter Wolf; Greisa Vila; Anton Luger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-28       Impact factor: 5.555

4.  Prevalence and outcome of comorbidities associated with acromegaly.

Authors:  Sven Berkmann; Joël Brun; Philipp Schuetz; Emanuel Christ; Luigi Mariani; Beat Mueller
Journal:  Acta Neurochir (Wien)       Date:  2021-04-15       Impact factor: 2.816

Review 5.  Insulin Resistance in Patients With Acromegaly.

Authors:  Greisa Vila; Jens Otto L Jørgensen; Anton Luger; Günter K Stalla
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-30       Impact factor: 5.555

6.  Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study of 64 Cases From a Large Pituitary Center in China.

Authors:  Zihao Wang; Lu Gao; Xiaopeng Guo; Chenzhe Feng; Kan Deng; Wei Lian; Ming Feng; Xinjie Bao; Bing Xing
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-01       Impact factor: 5.555

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Diabetes Mellitus Predicts Weight Gain After Surgery in Patients With Acromegaly.

Authors:  Han Na Jang; Yong Hwy Kim; Jung Hee Kim
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

9.  Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance.

Authors:  Enrica Menditto; Caitriona Cahir; Sara Malo; Isabel Aguilar-Palacio; Marta Almada; Elisio Costa; Anna Giardini; María Gil Peinado; Mireia Massot Mesquida; Sara Mucherino; Valentina Orlando; Carlos Luis Parra-Calderón; Enrique Pepiol Salom; Przemyslaw Kardas; Bernard Vrijens
Journal:  Int J Environ Res Public Health       Date:  2021-05-03       Impact factor: 3.390

Review 10.  Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.

Authors:  Soraya Puglisi; Francesco Ferraù; Marta Ragonese; Federica Spagnolo; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.